Cargando…

Clinical potential of apremilast in the treatment of psoriatic arthritis

Psoriatic arthritis (PsA) is a frequent chronic inflammatory disease characterized by joint and skin involvement, and by typical extra-articular manifestations. Although the pathogenesis of PsA is still under investigation, the available evidence suggests the importance of the patient’s genetic back...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cauli, Alberto, Porru, Giovanni, Piga, Matteo, Vacca, Alessandra, Dessole, Grazia, Mathieu, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918237/ https://www.ncbi.nlm.nih.gov/pubmed/27471702 http://dx.doi.org/10.2147/ITT.S40199

Ejemplares similares

Targeted Therapies in Axial Psoriatic Arthritis
por: Floris, Alberto, et al.
Publicado: (2021)

Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
por: Forchhammer, Stephan, et al.
Publicado: (2015)

Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis
por: Haddad, Amir, et al.
Publicado: (2023)

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2014)

Erratum to: Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2015)

Gene Expression Profiling of Monozygotic Twins Affected by Psoriatic Arthritis
por: Angioni, Maria Maddalena, et al.
Publicado: (2021)

Current perspective on the role of the interleukin-23/interleukin-17 axis in inflammation and disease (chronic arthritis and psoriasis)
por: Cauli, Alberto, et al.
Publicado: (2015)

The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis
por: Liu, Yong, et al.
Publicado: (2014)

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast
por: Palfreeman, Andrew C, et al.
Publicado: (2013)

Molecular profiling of clinical remission in psoriatic arthritis reveals dysregulation of FOS and CCDC50 genes: a gene expression study
por: Angioni, Maria Maddalena, et al.
Publicado: (2023)

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
por: Mease, Philip J., et al.
Publicado: (2020)

Ultrasonographic assessment of bone erosions in the different subtypes of systemic lupus erythematosus arthritis: comparison with computed tomography
por: Piga, Matteo, et al.
Publicado: (2016)

The arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-B*27:09
por: Cauli, Alberto, et al.
Publicado: (2013)

Clinical and ultrasonographic predictors for achieving minimal disease activity in patients with psoriatic arthritis: the UPSTREAM (Ultrasound in PSoriatic arthritis TREAtMent) prospective observational study protocol
por: Canzoni, Marco, et al.
Publicado: (2018)

Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report
por: Gualtierotti, Roberta, et al.
Publicado: (2019)

Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink
por: Persson, Rebecca, et al.
Publicado: (2022)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
por: Gladman, Dafna D., et al.
Publicado: (2020)

Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature
por: Garcovich, Simone, et al.
Publicado: (2020)

Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease—results of the Immune Metabolic Associations in Psoriatic Arthritis study
por: Ferguson, Lyn D, et al.
Publicado: (2021)

Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study
por: Becciolini, Andrea, et al.
Publicado: (2023)

Successful treatment with secukinumab in an HIV‐positive psoriatic patient after failure of apremilast
por: Romita, Paolo, et al.
Publicado: (2022)

The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast
por: Arias de la Rosa, Ivan, et al.
Publicado: (2022)

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
por: Kavanaugh, Arthur, et al.
Publicado: (2014)

Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis
por: Kawalec, P., et al.
Publicado: (2017)

Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective
por: Purmonen, Timo, et al.
Publicado: (2018)

Expression analysis of HLA-E and NKG2A and NKG2C receptors points at a role for natural killer function in ankylosing spondylitis
por: Cauli, Alberto, et al.
Publicado: (2018)

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial
por: Wells, Alvin F, et al.
Publicado: (2018)

Prognostic impact of coronary microcirculation abnormalities in systemic sclerosis: a prospective study to evaluate the role of non-invasive tests
por: Vacca, Alessandra, et al.
Publicado: (2013)

Polymyalgia rheumatica: an autoinflammatory disorder?
por: Floris, Alberto, et al.
Publicado: (2018)

Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab: an alternative to standard of care
por: Chessa, Elisabetta, et al.
Publicado: (2017)

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies
por: Gladman, Dafna D, et al.
Publicado: (2018)

Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis
por: Hagberg, Katrina Wilcox, et al.
Publicado: (2020)

Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study
por: de Vlam, Kurt, et al.
Publicado: (2022)

Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study
por: Pina Vegas, Laura, et al.
Publicado: (2021)

Comparison between methotrexate and apremilast in Psoriatic Arthritis-a single blind randomized controlled trial (APREMEPsA study)
por: Samanta, Joydeep, et al.
Publicado: (2023)

The effect of Apremilast on signal transduction and IL-10 production in CD39high regulatory B cells in patients with psoriatic arthritis
por: Sakkas, Lazaros I., et al.
Publicado: (2018)

Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study
por: Suruki, Robert Y, et al.
Publicado: (2022)

Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
por: Sfikakis, Petros P., et al.
Publicado: (2023)

Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic
por: Das, Ashis K., et al.
Publicado: (2023)

Acrodermatitis continua of Hallopeau: Is apremilast an efficacious treatment option?
por: Megna, Matteo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fq56v8itjgr43lpjt45f51rqni